Biotechnology stocks
13 US-listed companies in biotechnology, part of the Health Care sector, with a combined market value of $1.48 trillion at the close on Oct 30, 2026. Their median P/E is 37.0 and their median one-year return +37.8%.
Biotechnology stocks, largest first
| Company | Price | 1 year | Market value | P/E |
|---|---|---|---|---|
| AbbVieABBV | $294.89 | +33.1% | $521B | 83.3 |
| AmgenAMGN | $466.01 | +64.0% | $252B | 29.0 |
| Gilead SciencesGILD | $170.68 | +47.7% | $212B | — |
| Vertex PharmaceuticalsVRTX | $558.88 | +33.1% | $142B | 32.6 |
| RegeneronREGN | $927.89 | +42.6% | $97.3B | 23.0 |
| ModernaMRNA | $221.72 | +687.9% | $88.0B | — |
| BiogenBIIB | $253.62 | +69.5% | $37.5B | 109.3 |
| CibusCBRS | $109.18 | — | $24.7B | — |
| InsmedINSM | $112.58 | -42.0% | $24.6B | — |
| IncyteINCY | $120.39 | +30.0% | $24.4B | 64.0 |
| BioNTechBNTX | $88.17 | -15.8% | $22.3B | — |
| Alnylam PharmaceuticalsALNY | $165.00 | -63.3% | $22.1B | 41.5 |
| ExelixisEXEL | $69.39 | +78.2% | $17.2B | 20.7 |
No forecast, no recommendation. A list of companies by industry is not advice to buy, sell or hold any of them.